Goal: Conduct a series of high-impact studies that will ideally lead to about 15 Investigational New Drugs (INDs), which would then produce around five New Drug Applications (NDAs) submitted to the Food and Drug Administration (FDA).
This project will focus on developing new addiction treatments and overdose-reversal tools. Three medications are currently FDA-approved to treat opioid addiction, and naloxone is available in both injectable and intranasal formulations to reverse overdose. But a wider range of options is needed in both areas. These may involve new formulations of existing drugs including longer-acting depot formulations of opioid agonists as well as stronger, longer-lasting naloxone formulations to more effectively reverse overdose from powerful synthetic opioids such as fentanyl. Research will also focus on compounds that target different receptor systems or immunotherapies to treat symptoms of withdrawal and craving in addition to the progression of opioid use disorders.
NIDA Contact: Dr. Kurt Rasmussen
Grants Awarded to Date
- 9/6/2018: Evaluation of Safety and Pharmacokinetics of Naltrexone Implant
- 9/6/2018: Phase 1A/1B Clinical Trials of Multivalent Opioid Vaccine Components
- 9/6/2018: An Ultra-Long-Acting Oral Treatment for Opioid Use disorder
- 9/6/2018: Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder
- 9/6/2018: Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders
- 9/6/2018: PF614 MPAR Abuse Deterrent Opioid Prodrug with Overdose Protection: Pre-Clinical Development and Phase 1 Clinical Trial
Emerging Trends & Alerts
Get more information on Emerging Trends and Alerts, we will update this page with the latest research findings as they develop.
Get this Publication
Find information about addiction and mental health services in your area. You can search by state or zip code online or call the number. (SAMHSA)